Abstract
Pituitary adenomas with clinically relevant hypersecretion comprise approximately 40% of all pituitary adenomas. The most frequent is the prolactinoma. For more than 30 years this tumor has been regularly treated primarily by dopamine agonists. Thus, mostly tumor shrinkage and normalization of prolactin plasma levels have been achieved. Intolerance and partial effi-cacy are indications for a surgical approach. A parallel comparison of medically pretreated and only surgically treated patients showed significant differences that are of importance to the surgeon and pathologist. In acromegaly, specific medications with somatostatin analogues became available more than 20 years ago. In most cases with or, increasingly rarely, without pre-treatment, transnasal microsurgery is performed with the option of long-lasting clinical remission. In incompletely resectable adenomas, the discussed indication for surgery involves improvement of the effects of medical treatment and reduction of the radiation field. New pharmaceutical approaches with a GH-receptor antagonist optionally in combination with somatostatin analogues and or dopamine-agonists challenge the surgical options. TSH-secreting adenomas are extremely rare and may also be successfully treated by soma-tostatin analogues. After shrinkage or without gross invasion and improved microsurgical techniques, longterm results are promising. All these adenomas have tumor markers with a short half-life in plasma and may be checked during or shortly after surgery. Pretreatments influence the assessment, which has to be taken into consideration. In Cushing's disease, measurement of ACTH and cortisol the day after surgery mostly clarifies the effect of surgery. In selected primary failures, early re-operation may be successfully performed. Nowadays, the diagnosis (late-night cortisol, CRH test) and follow-up can easily be done with salivary cortisol. Medical options with more adenoma-specific ligands (Pasireotide) are under clinical evaluation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Barkan AL, Chandler WF. (1998) Giant pituitary adenoma with falsely low serum prolactin: the pitfall of the “high dose hook effect.” Neurosurgery 42:913–915
Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. NEJM 349:2023–2033
Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G. (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. JCEM 85:2247–2252
Hattori N. (2003) Macroprolactinemia: a new cause of hyperprolactinemia. J Pharmacol Sci 92:171–177
Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L, Beckers A. (2008) Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 159:1–5
Lüdecke DK, Herrmann H-D, Hörman C, Desaga U, Saeger W. (1983) Microsurgery and combination with dopamine agonist treatment of prolactinomas. In: Tolis G et al. (eds) Prolactin and prolactinomas. Raven, New York, pp. 453–467
Molitch ME. (2001) Disorders of prolactin secretion. Endocrinol Metab Clin North Am 30:585–610
Attanasio R, Epaminonda P, Motti E, Giugni E, Ventrella L, Cozzi R, Farabola M, Loli P, Beck-Peccoz P, Arosio M. (2003) Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J Clin Endocrinol Metab 88:3105–3112
Biermasz NR, van Dulken H, Roelfsema F. (2000) Longterm follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 85:2476–2482
Clemmons DR, Chihara K, Freda PU, Ho KKY, Klibanski A, Melmed S, Shalet SM, Strasburger CJ, Trainer PJ, Thorner MO. (2003) Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 88:4759–4767
Freda PU. (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013–3018
Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, von Werder K, Melmed S. (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526–529
Lüdecke DK. (1985) Recent developments in the treatment of acromegaly. Neurosurg Rev 8:167–173
Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, von Werder K, Wass J, Giustina A. (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054–4058
Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ. (2007) Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 92:4598–4601
Abe T, Lüdecke DK. (2001) Effects of preoperative oct-reotide treatment on different subtypes of 90 growth hormone-secreting pituitary adenomas and outcome in one surgical center. Eur J Endocrinol 145:137–145
Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. (1996) Thyrotropin-secreting pituitary tumors. Endocr Rev 17:610–638
Buchfelder M, Fahlbusch R. (2001) Thyrotroph adenomas. In: Thapar K, Kovacs K, Scheithauer BW, Lloyd RV (eds) Diagnosis and management of pituitary tumors. Humana, Totowa, NJ, pp. 333–342
Chanson P, Weintraub BD, Harris AG. (1993) Octreotide therapy for thyroid stimulating-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 119:236–240
Kourides IA, Ridgway EC, Weintraub BD, Bigos ST, Gershengorn MC, Maloof F. (1977) Thyrotropin-induced hyperthyroidism: use of α and β subunit levels to identify patients with primary tumors. J Clin Endocrinol Metab 45:534–543
Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P. (1996) Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 81:3084–3090
McCutcheon IE, Weintraub BD, Oldfield EH. (1990) Surgical treatment of thyreotroph adenomas. J Neurosurg 73:674–683
Saeger W, Lüdecke DK. (1982) Pituitary adenomas with hyperfunction of TSH: frequency, histological classification, immunocytochemistry and ultrastructure. Virchows Arch [Pathol Anat] 394:255–267
Asa SL, Kovacs K, Tindall GT, Barrow DL, Horvath E, Vecsei P. (1984) Cushing's disease associated with an intra-sellar gangliocytoma producing corticotropin-releasing factor. Ann Intern Med 101:789–793
Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A. (2006) The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91:4482–4488
Biller BMK, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JAH, Boscaro M. (2008) Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454–2462
Cushing H. (1932) The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophil-ism). Bull Johns Hopkins Hosp 50:137–195
Flitsch J, Spitzner S, Lüdecke DK. (2000) Emotional disorders in patients with different types of pituitary adenomas and factors affecting the diagnostic process. Exp Clin Endocrinol Diabetes 108:480–485
Hoffmann BM, Hlavac M, Martinez R, Buchfelder M, Müller OA, Fahlbusch R. (2008) Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg 108:9–18
Lüdecke DK. (1989) Intraoperative measurement of adreno-corticotrophic hormone in peripituitary blood in Cushing's disease. Neurosurg 24:201–204
Lüdecke DK, Flitsch J, Knappe UJ, Saeger W. (2001) Cushing's disease: a surgical view. J Neuro-Oncol 54:151–166
Mahmoud-Ahmed AS, Suh JH. (2002) Radiation therapy for Cushing's disease: a review. Pituitary 5:175–180
Nelson DH, Meakin JF, Dealy JW, Matson DD, Emerson K, Thorn GW. (1958) ACTH-producing tumor of the pituitary gland. N Engl J Med 259:161–164
Newell-Price J, Trainer P, Besser M, Grossman A. (1998) The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 19:647–672
Nieman LK. (2002) Medical therapy of Cushing's disease. Pituitary 5:77–82
Oldfield EH, Chrousos GP, Schulte HM, Schaaf M, Mc Keever PE, Krudy AG, Cutler Jr GB, Loriaux DL, Doppman JL. (1985) Preoperative lateralization of ACTH-secreting pituitary microadenomas by bilateral and simultaneous inferior petrosal venous sinus sampling. N Engl J Med 312:100–103
Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L, Laws ER Jr. (2008) Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 93:358–362
Saeger W, Wilczak P, Lüdecke DK, Buchfelder M, Fahlbusch R. (2003) Hormone markers in pituitary adenomas: Changes within last decade resulting from improved method. Endocr Pathol 14:49–54
Semple PL, Laws Jr ER. (1999) Complications in a contemporary series of patients who underwent transsphenoidal surgery. J Neurosurg 91:175–179
Solcia E, Klöppel G, Sobin LH, Capella C, de Lellis RA, Heitz PhU, Horvath E, Kovacs K, Lack EE, Lloyd RJ, Rosai J, Scheithauer BW. (2000) Histological typing of endocrine tumors. 2nd ed. Springer, Berlin/Heidelberg/ New York/Barcelona/Hong Kong/London/Milan/Paris/ Singapore/Tokyo
Teramoto A, Nemoto S, Takakura K, Sasaki Y, Machida T. (1993) Selective venous sampling directly from the cavernous sinus in Cushing's syndrome. J Clin Endocrinol Metab 76:637–641
Acknowledgments
We thank Mrs. H.P. Flitsch for her assistance with the English language of 13.5 and Ass. Prof. P. A. Crock for proofreading
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lüdecke, D.K., Abe, T., Flitsch, J., Petersenn, S., Saeger, W. (2010). Functioning Adenomas. In: Tonn, JC., Westphal, M., Rutka, J.T. (eds) Oncology of CNS Tumors. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-02874-8_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-02874-8_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-02873-1
Online ISBN: 978-3-642-02874-8
eBook Packages: MedicineMedicine (R0)